Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Per the activity note to the FY2023 annual report, the company carries out wholesale trade in pharmaceutical products.
| Line item | 2018 | 2019 | 2022 | 2023 | CAGR |
|---|---|---|---|---|---|
| Total Revenue | 3,667 | 2,855 | 4,122 | 3,535 | -0.7% |
| Total COGS | 2,907 | 2,059 | 2,632 | 2,476 | -3.2% |
| Gross Profit | 761 | 796 | 1,490 | 1,059 | +6.8% |
| Gross Margin | 20.7% | 27.9% | 36.1% | 30.0% | |
| 595 | 590 | 744 | 824 | +6.7% | |
| EBITDA | 166 | 206 | 746 | 235 | +7.2% |
| EBITDA Margin | 4.5% | 7.2% | 18.1% | 6.6% | |
| Total D&A | 83 | 83 | 0 | 52 | -9.0% |
| EBIT / Operating Income | 82 | 123 | 746 | 183 | +17.3% |
| Total Interest Expense | 92 | 101 | 82 | 15 | -30.5% |
| 110 | 417 | 37 | 2 | nmf | |
| Profit Before Tax | 101 | 395 | 701 | 166 | +10.4% |
| Total Income Tax | 0 | 0 | 0 | 0 | |
| Net Profit / (Loss) | 101 | 395 | 701 | 166 | +10.4% |
| Net Margin | 2.8% | 13.8% | 17.0% | 4.7% | |
| Other Comprehensive Income | 71 | 0 | 0 | 0 | |
| Total Comprehensive Income | 172 | 395 | 701 | 166 | -0.7% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set.